Literature DB >> 10737831

Antipsychotic drug use patterns and the cost of treating schizophrenia.

J S McCombs1, M B Nichol, B M Johnstone, G L Stimmel, J Shi, R Smith.   

Abstract

This study investigated the relationships between antipsychotic drug use patterns and direct costs for 3,321 Medi-Cal patients with schizophrenia. Ordinary least-squares regression models were used to estimate the impact on costs of receiving antipsychotic drug treatment, delays in treatment, changes in therapy, and continuous therapy. Average costs were $25,940 per year per patient. Having used an antipsychotic drug was correlated with lower psychiatric hospital costs ($2,846 less) but higher nursing home costs. Completing one year of uninterrupted drug therapy was correlated with higher nursing home costs. Delayed drug treatment and changes in therapy increased the cost by $9,418 and $9,719, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737831     DOI: 10.1176/appi.ps.51.4.525

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  6 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia.

Authors:  Susan dosReis; Elizabeth Johnson; Donald Steinwachs; Charles Rohde; Elizabeth A Skinner; Maureen Fahey; Anthony F Lehman
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

Review 3.  Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review.

Authors:  Natascha Wilson; Jean Lud Cadet
Journal:  J Addict Dis       Date:  2009-10

Review 4.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

5.  Open access to innovative drugs: treatment substitutions or treatment expansion?

Authors:  Jeffrey S McCombs; Parvez Mulani; P Joseph Gibson
Journal:  Health Care Financ Rev       Date:  2004

6.  Use of conventional antipsychotics and the cost of treating schizophrenia.

Authors:  R R Lyu; J S McCombs; B M Johnstone; D N Muse
Journal:  Health Care Financ Rev       Date:  2001
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.